Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Delcath Systems has announced that the John Wayne Cancer Institute at Saint John's Health Center in Santa Monica, California, has joined the company's Phase III clinical trial for the treatment of metastatic melanoma in the liver.
Subscribe to our email newsletter
John Wayne Cancer Institute (JWCI) is the eighth center in this multi-center trial testing the company’s percutaneous hepatic perfusion system for the isolated, high-dose delivery of the anticancer agent melphalan.
Delcath and JWCI have entered into a clinical research agreement to conduct the Phase III National Cancer Institute led study.
Richard Taney, president and CEO of Delcath, stated: “We are delighted to be working with Faries and JWCI, and to be able to provide this treatment modality to patients on the west coast of the US. JWCI’s and Faries’s reputation and commitment to cutting-edge cancer treatment and their focus on melanoma make this an ideal site to be part of this trial. The company will build on the momentum that the new sites bring to this trial, and we anticipate completion of enrollment in 2009.”